Title

The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy
An Open Label, Randomized, Multicenter Clinical Trial to Compare the Efficacy and Safety of Lamotrigine / Valproate Coadministration and Carbamazepine as Initial Pharmacotherapy in Epilepsies (Phase Ⅳ)
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Study Participants

    207
To evaluate the efficacy of usual monotherapy and low dose combination of Lamotrigine and Valproate. Low dose combination may be more effective and tolerable because they are low dose and VPA reduce Lamotrigine metabolism.
An Open label, Randomized, Multicenter Clinical Trial to Compare the Efficacy and Safety of Lamotrigine / Valproate Coadministration and Carbamazepine as Initial Pharmacotherapy in Epilepsies
Study Started
Mar 31
2008
Primary Completion
May 31
2012
Study Completion
May 31
2012
Results Posted
May 29
2015
Estimate
Last Update
Jul 27
2015
Estimate

Drug Carbamazepine

Drug Lamotrigine/Valproate

Carbamazepine Active Comparator

Carbamazepine

Lamotrigine/Valproate Experimental

Lamotrigine and Valproate combination therapy

Criteria

Inclusion Criteria:

Age ≥16yr old
Who are diagnosed as epilepsy definitely
Who have minimum 2 unprovoked seizures and minimum 1 seizure in previous 3 months
Who need AED therapy and no AED medication for previous 1 year (exclude emergency medication for less than 2weeks)
Who is not pregnant
Who can report seizure diary by him/herself or caregiver
Who agree to this trial and provide informed consent.
Type of seizures : of generalized tonic-clonic, complex partial, and/or simple partial motor seizures;

Exclusion Criteria:

Who has progressive CNS disease.
Has serious systemic or psychiatric disease
Who is not suitable by investigator(uncooperative)
Who can not fill up diary check card
Is pregnant, breastfeeding, or planning to become pregnant
Exclusion - absence s. juvenile myoclonic epilepsy, atonic seizure, alcohol or other substance abusers, mental retardation etc.
Who cancels to agree to this trial and provide informed consent.
ALT, AST, bilirubin and BUN/Cr levels are more than twice normal range of them
WBC value is 2000 and less, Hb value is 9.0 and less, platelet count is 100,000 and less in CBC
Who took investigation products before participating this study

Summary

Carbamazepine

Lamotrigine/Valproate

All Events

Event Type Organ System Event Term Carbamazepine Lamotrigine/Valproate

Retention Rate After 52 Weeks Maintenance Period

* Retention rate means completion rate (CR), the proportion of patients who have completed the 60-week study as planned.

Carbamazepine

104.0
participants

Lamotrigine/Valproate

98.0
participants

Seizure Free Rate for 24 Weeks at Initial Target Dose

Carbamazepine

51.0
participants

Lamotrigine/Valproate

59.0
participants

Seizure Free Rate for 52 Weeks at Initial Target Dose

Carbamazepine

43.0
participants

Lamotrigine/Valproate

50.0
participants

Total

202
Participants

Age, Continuous

34.8
Year (Mean)
Standard Deviation: 14.2

Region of Enrollment

Sex: Female, Male

Overall Study

Carbamazepine

Lamotrigine/Valproate